The efficacy number cut in half, the regulatory path looked murkier
In the long arc of pandemic medicine, promising treatments often meet the humbling complexity of larger truths. Merck's oral Covid-19 pill molnupiravir, once heralded as a breakthrough with 50 percent efficacy, has revealed itself to be a more modest instrument — reducing hospitalizations and deaths by 30 percent when measured across a fuller population of over 1,400 patients. As FDA advisers prepare to vote on its authorization, the world watches a familiar tension unfold: the urgency to act against a relentless disease weighed against the discipline of knowing what a medicine can truly do.
- What was announced as a 50 percent efficacy breakthrough in October has now been revised sharply downward to 30 percent, shaking confidence in one of the most anticipated Covid-19 treatments.
- A death recorded in the treatment group — absent in the earlier data snapshot — adds a sobering human dimension to the statistical revision.
- Merck's stock fell 3 percent in pre-market trading, signaling that markets, like regulators, are recalibrating expectations around a drug that had been priced into optimism.
- FDA expert advisers are set to vote Tuesday on whether a 30 percent reduction in hospitalizations is meaningful enough to justify authorization for high-risk adults.
- The drug's greatest remaining argument is its form — an oral pill taken at home — but efficacy questions now sit squarely at the center of a consequential regulatory decision.
Merck disclosed on Friday that molnupiravir, its experimental Covid-19 pill developed with Ridgeback Biotherapeutics, is significantly less effective than the company had suggested just weeks prior. Updated trial data from more than 1,400 patients showed the drug reducing hospitalizations and deaths by 30 percent — a steep fall from the 50 percent figure Merck had announced in October based on an interim look at 775 patients.
The earlier snapshot had been striking: hospitalizations cut nearly in half, and no deaths in the treatment group. The completed trial told a quieter story. The molnupiravir group saw a 6.8 percent hospitalization rate against 9.7 percent for placebo — a real but reduced advantage — and one patient in the treatment arm had died. The revision was not a scandal, but a demonstration of how pharmaceutical data can shift as trials grow.
The news moved markets. Merck shares slid 3 percent in pre-market trading, a reflection of how much the drug's commercial and symbolic value had been tied to that initial 50 percent figure. The company had filed for U.S. authorization on October 11th, carried by early momentum that now looked premature.
FDA advisers are scheduled to vote Tuesday on whether to recommend authorization of the oral capsules for adults at high risk of severe Covid-19. The agency's own scientists were expected to release their assessment documents as early as Friday, giving the panel time to absorb the revised picture before deliberating. The central question before them is whether 30 percent protection — delivered through a pill patients can take at home — constitutes a meaningful enough contribution to warrant a place in the medical arsenal against a disease that continues to exact its toll.
Merck announced Friday that its experimental Covid-19 pill was far less potent than the company had claimed just weeks earlier. The drug, molnupiravir, developed jointly with Ridgeback Biotherapeutics, reduced hospitalizations and deaths by 30 percent according to updated trial data—a sharp drop from the 50 percent efficacy the company had trumpeted in October based on preliminary results.
The shift reflected what happens when pharmaceutical trials expand. In October, Merck's interim analysis involved 775 patients and showed molnupiravir cutting hospitalizations to 7.3 percent compared to 14.1 percent in the placebo group, with no deaths in the treatment arm. When the company completed enrollment and analyzed data from more than 1,400 patients, the picture changed. The hospitalization rate in the molnupiravir group fell to 6.8 percent—still better than the 9.7 percent rate among those given placebo—but one person in the treatment group had died, whereas the earlier snapshot showed none.
The news landed hard on Wall Street. Merck's stock dropped 3 percent in pre-market trading to $79.80, sliding along with broader market weakness. The company had filed for U.S. authorization of molnupiravir on October 11, riding the momentum of those initial findings. Now, with the efficacy number cut in half, the regulatory path forward looked murkier.
The Food and Drug Administration's expert advisers were scheduled to meet Tuesday to vote on whether to recommend approval of the oral capsules for treating mild-to-moderate Covid-19 in adults at high risk of severe disease. The agency's own scientists were expected to publish their assessment documents as early as Friday, giving the panel time to digest the revised data before the vote. That timing meant the advisory committee would be weighing a drug whose real-world promise had visibly diminished even as it moved through the approval process.
What remained unclear was whether a 30 percent reduction in hospitalizations and deaths would be enough to convince regulators that molnupiravir deserved authorization. The drug was an oral treatment—a significant advantage over intravenous therapies—and it was designed for people who could take it at home early in their illness. But efficacy matters, and the gap between 50 percent and 30 percent is not a rounding error. The FDA panel's decision would hinge on whether they viewed that level of protection as meaningful enough to offer patients and doctors another tool in the fight against severe Covid-19.
Citas Notables
Merck said its pill showed a 30 percent reduction in hospitalizations and deaths, based on data from over 1,400 patients— Merck
La Conversación del Hearth Otra perspectiva de la historia
Why did the efficacy number drop so dramatically between October and now?
The October data came from 775 patients—an interim snapshot taken partway through the trial. When Merck enrolled the full 1,400-plus patients and ran the complete analysis, the effect size shrank. That's not unusual in drug trials, but it's always a jolt when it happens this visibly.
Does a 30 percent reduction still count as meaningful?
That depends on the alternative. If you're someone at high risk of hospitalization and you have a pill you can take at home that cuts your risk by nearly a third, that's not nothing. But it's also not the 50 percent protection people thought they were getting.
What happens to the company's credibility now?
Merck didn't manipulate the data—they reported what they found at each stage. But they did file for FDA authorization based on the interim results, which means they were betting on those numbers holding. Now they have to defend a weaker case.
Will the FDA panel approve it anyway?
That's the real question. The panel meets Tuesday. They'll have to decide if 30 percent efficacy, combined with the convenience of an oral pill, is worth authorizing. Some will say yes. Others might argue the benefit is too modest.
What about that one death in the treatment group?
It's a single event in a trial of over 1,400 people, so it's hard to draw firm conclusions. But it does mean molnupiravir isn't risk-free, and it's no longer a treatment with zero deaths in the data.